Watson Pharmaceuticals Confirms Favorable Court Decision Regarding Generic Actos Approval

Watson Pharmaceuticals

today confirmed that U.S. District Court for the District of Columbia has granted summary judgment in favor of Watson and ordered the U.S. Food and Drug Administration (FDA) to approve Watson's generic version of Actos (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets).   Watson plans to begin shipping the product immediately upon receipt of final FDA approval. On August 15, 2012, Watson announced that it had filed suit against the FDA challenging the Agency's decision regarding Watson's entitlement to shared exclusivity for its generic version of Actos (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets).